News and Trends 27 Jun 2022 Covid vaccine granted marketing authorization in Europe Specialty vaccine company, Valneva, has been given marketing authorization in Europe for its inactivated whole-virus COVID-19 vaccine VLA2001. This is a turnaround from the company’s situation in May of this year when the stock price was knocked down by 20% when gaining traction in the EU was proving to be a struggle. Despite authorization from […] June 27, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 24 Jun 2022 Study reveals progress for those with hepatitis B A clinical-stage biopharma company has announced its study of product VTP-300 for use in patients with hepatitis B has resulted in positive safety and efficacy data. Vaccitech plc deals with novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, cancer, and autoimmune diseases. The updated analysis includes 39 patients with at least […] June 24, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 24 Jun 2022 Covid and malaria vaccines on track for mass production in Rwanda Construction of the first African messenger RNA (mRNA) manufacturing facility has started in Africa. This means Biopharmaceutical New Technologies (BioNTech) SE is a step closer to producing mRNA vaccines that teach human cells how to make a protein that will trigger an immune response inside the body. The company is a next generation immunotherapy company […] June 24, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 23 Jun 2022 Osivax gets €10M influenza vaccine grant A grant of €10 million ($10.5 million) has been secured by pharmaceutical company Osivax to support a vaccine against influenza. The biopharma company develops vaccines to provide broad-spectrum protection against highly mutating infectious viruses and diseases. It announced today (June 23) that it has secured the funds from Bpifrance to support the further clinical development […] June 23, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
Sponsored by Merck 23 Jun 2022 How a global network accelerated the development of a virus-like particle vaccine against Covid-19 Vaccines are among the most effective ways to improve and protect human health. Whereas vaccines in Europe and North America are regarded as part of the general medical plan, vaccine supply has always been a pressing issue in African countries. In the current Covid-19 pandemic, the ability to develop and manufacture vaccines in Africa instead […] June 23, 2022 - 5 minutesmins - By Ute Boronowsky Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jun 2022 Millions invested for progression of Lyme disease vaccine Pfizer has agreed to invest €90.5 million ($95 million) towards a vaccination for Lyme disease. A deal has been struck with Valneva SE that will see the start of the phase 3 study of the disease’s vaccine candidate, VLA15. This is scheduled for the third quarter of this year. The investment will represent 8.1% of […] June 22, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jun 2022 US Toddlers and children to receive Covid-19 vaccine after emergency approval granted Emergency authorization was granted for the use of the Pfizer-BioNTech Covid-19 vaccines on children from six months old to under five years of age. The US Food and Drug Administration made the authorization on Friday (June 17). All children ages 6 months and up are now eligible to receive the COVID-19 vaccine, following the US […] June 22, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jun 2022 From mugwort allergy to an effective vaccine? A research team at MedUni Vienna in Austria says it has discovered key mechanisms of allergy to pollen from the common weed mugwort, which could lay the foundation for the development of the world’s first vaccine. Mugwort (Artemisia vulgaris) poses a serious problem for some people with allergies in places where the plant is common […] June 22, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jun 2022 Eurocine Vaccines expands portfolio to develop HSV-2 vaccine Swedish company Vaccines AB (Eurocine Vaccines) has entered into a research and collaboration agreement with Redbiotec AG. The agreement gives Eurocine Vaccines the exclusive global rights to develop, manufacture and commercialize vaccine candidates against Herpes Simplex Virus Type 2 (HSV-2), based on technologies developed by Swiss biotech company Redbiotec. The agreement covers both an mRNA […] June 15, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 13 Jun 2022 GSK positive on RSV vaccine for older adults GSK plc has announced positive headline results from its AReSVi 006 phase III trial. AReSVi 006 is a phase III trial investigating GSK’s respiratory syncytial virus (RSV) vaccine candidate for adults aged 60 years and above. GSK said no unexpected safety concerns were observed. Dr Hal Barron, chief scientific officer and president, R&D, GSK, said, […] June 13, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jun 2022 Ziphius Vaccines and University of Antwerp to work on RNA-based delivery methods Belgian biopharma firm Ziphius Vaccines is set to collaborate with the University of Antwerp to research and develop a lipid library for optimized delivery systems of self-amplifying RNA-based drugs (saRNA) and therapeutics. Messenger RNA (mRNA) vaccines deliver genetic instructions to cells to create proteins that then train the immune system against a pathogen, such as […] June 9, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jun 2022 Cancer vaccine biotech CimCure raises €5M Dutch biotech company CimCure, which is focusing on the development of vaccine-based cancer immunotherapy, has raised more than €5M ($5.3M) in a financing seed round led by Dutch company Positron Ventures. CimCure, a spin-off of the Amsterdam UMC medical center, is set to use the funds to advance its vaccine up to phase 1-2 clinical […] June 7, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email